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Abstract: 
Exposure to high levels of manganese (Mn) results in a neurological disorder, termed manganism, which shares 
a similar phenotype to Parkinson’s disease due to the involvement of the basal ganglia circuitry in both. The 
initial symptoms of manganism are likely due to the involvement of the globus pallidus, a region rich in γ-
aminobutyric acid (GABA) projections, while those of Parkinson’s disease are related to the degeneration of the 
substantia nigra, a dopaminergic nucleus. Additionally, it is known that glutamate regulation is affected by 
increases in brain Mn levels. As Mn predominantly accumulates in the basal ganglia, it potentially could affect 
the regulation and interactions of all three neurotransmitters. This review will focus on the circuitry of these 
neurotransmitters within the basal ganglia and address potential sites for, as well as the temporal relationship, 
between Mn exposure and changes in the levels of these neurotransmitters. While most research has focused on 
perturbations in the dopaminergic system, there is evidence to support that early consequences of manganism 
also include disturbances in GABA regulation as well as glutamatergic-related excitotoxicity. Finally, we 
suggest that current research focus on the interdependence of these basal ganglial neurochemicals, with a 
greater emphasis on the GABAergic and glutamatergic systems. 
Keywords: Manganese neurotoxicity; Glutamate; Dopamine; GABA; Basal ganglia 
 
Article: 
1. Introduction 
Manganese (Mn) is a naturally occurring element present not only in the earth’s crust, but also in many foods. 
Mn is an essential trace element, and under most conditions, humans consume sufficient amounts of Mn in their 
diet. However, occupations, such as Mn mining (Garcia-Avila and Penalver-Ballina, 1953; Rodier, 1955; Myers 
et al., 2003) and welding (Racette et al., 2001; Levy and Nassetta, 2003; Sadek et al., 2003) may present a 
greater risk for exposure, and by inference brain accumulation, of this metal. Under these circumstances, signs 
and symptoms characteristic of Mn toxicity have been recognized. Recent concern related to Mn exposure has 
also focused on the use of a Mn-containing fuel additive, methylcyclopentadienyl Mn tri-carbonyl (MMT), as 
an anti-knock agent in gasoline in Canada and other Western nations (Ressler et al., 1999; Bolte et al., 2004; 
Pfeifer et al., 2004; Rollin et al., 2005). Other data from animal studies suggest that iron deficiency or anemia 
may also be a risk factor for Mn neurotoxicity (Finley, 1999; Erikson et al., 2002a; Kim et al., 2005). It is also 
well documented that individuals with chronic liver disease (Hauser et al., 1996; Rose et al., 1999; Montes et 
al., 2001; Racette et al., 2005), or those receiving parenteral nutrition (Fitzgerald et al., 1999; Bertinet et al., 
2000; Takagi et al., 2001), also accumulate high brain Mn levels. 
 
Following chronic exposure to high levels of Mn, patients may present with early psychiatric symptoms, such as 
increased anxiety, insomnia and irritability (Calne et al., 1994; Pal et al., 1999). Later, as the disorder 
progresses, they demonstrate movement abnormalities, including dystonia and difficulty in walking backwards 
(Calne et al., 1994; Pal et al., 1999). Although somewhat similar in presentation to idiopathic Parkinson’s 
disease (IPD), it can be distinguished by the general lack of responsiveness to dihydroxyphenylalanaine (L-
DOPA), a highly effective drug used to treat IPD, and the rarity of tremor. 
 
 
 
1.1. The basal ganglia circuitry 
It is perhaps not surprising that IPD and manganism share similarities in their clinical presentations. Both 
diseases affect the basal ganglia, and both include perturbations of the dopaminergic system. However, their 
pathological etiologies are quite different. For example, IPD results from the loss of the pigmented 
dopaminergic neurons in the substantia nigra pars compacta (Obeso et al., 2002). On the other hand, Mn 
initially accumulates in the globus pallidus, a nucleus with y-aminobutyric acid (GABA) projections (Calne et 
al., 1994; Pal et al., 1999). Additionally, it has been hypothesized that at least some of the cell death observed in 
animals given high doses of Mn may be due to excitotoxic lesions from high extracellular levels of glutamate 
(Glu) (Hazell, 2002; Normandin and Hazell, 2002; Takeda, 2003). It is likely that the characteristics of 
manganism are due to the interactions of all three of these basal ganglial neurotransmitters. 
 
The nuclei comprising the basal ganglia are responsible for integrating and coordinating information from 
various brain regions associated with motor movement. As diagrammed in Fig. 1a, the circuitry of basal ganglia 
is comprised of the following discrete nuclei: globus pallidus, substantia nigra, subthalamic nucleus and the 
striatum (caudate and putamen). However, the circuit also sends and receives information from the cortex and 
thalamus. When viewed from the standpoint of a circuit, rather than individual nuclei, it becomes more apparent 
why IPD and manganism share a common phenotype, as both the globus pallidus and substantia nigra can 
ultimately be affected in both entities. 
 
With this framework in mind, it is reasonable to hypothesize that an initial insult to the globus pallidus during 
Mn neurotoxicity could result in decreased inhibitory GABA input to the subthalamic nucleus. This would 
potentially lead to dysinhibition of the down-stream Glu output to the substantia nigra (Fig. 1b), leading to 
chronic over-stimulation. A similar scenario can be described for IPD. Here, the initial site of damage is the 
substantia nigra (Fig. 1c), resulting in a two-fold problem: firstly, decreased dopamine (DA) output to the 
striatum would indirectly result in deregulation of the globus pallidus; secondly, dysinhibition of the thalamus 
could lead to increased Glu output to the neurons in the thalamo-cortical pathway. The overall result of injury to 
the substantia nigra during IPD thus affects the globus pallidus, while damage to the globus pallidus from Mn 
accumulation subsequently affects the substantia nigra. 
 
Although not thought to be directly related to IPD or Mn neurotoxicity, the glutamatergic system of the basal 
ganglia is also disrupted in both disorders, due to the involvement of either the thalamus or the subthalamic 
nucleus, respectively. Glu deregulation can lead to significant cellular consequences, as excess extracellular Glu 
and its ensuing excitotoxicity are well documented (Danbolt, 2001). 1.2. Neurotransmitters of the basal ganglia 
GABA is the main inhibitory neurotransmitter in the brain. Its production is intimately related to the regulation 
of Glu through the astrocytes (Fig. 2). Indeed, it is astrocytes that remove Glu from the synaptic cleft following 
neurotransmission (Aschner et al., 1999; Aschner, 2000; Normandin and Hazell, 2002). Glu is then converted to 
glutamine (Gln) and released from astrocytes for uptake by neurons. Finally, Gln is converted back to Glu in 
glutamatergic neurons, or to GABA in GABAergic neurons. It is also known that GABA dysfunction is 
associated with various psychiatric disorders, such as schizophrenia, bipolar disorder and major depression 
(Torrey et al., 2005), which share symptomology with the early stages of manganism. 
 
 
DA is an important catecholamine in the brain associated with the regulation of locomotor activity, emotion and 
neuroendocrine secretion (Cooper et al., 1996b). The synthesis of DA is unrelated to that of Glu or GABA (Fig. 
3). Dopaminergic, as well as other catecholaminergic neurons, use the amino acid tyrosine as the initial starting 
material for neurotransmitter synthesis. Following two metabolic steps, DA is available for neural transmission. 
Glu is the most abundant excitatory neurotransmitter in the brain. It has been proposed that Glu plays several 
major roles in normal brain function such as cognition, learning and memory as well as development of the 
central nervous system, including synapse induction and elimination, cell migration, differentiation and death 
(Cooper et al., 1996a). Furthermore, Glu also plays a signaling role in peripheral organs and tissues, as well as 
in endocrine cells (Danbolt, 2001). As mentioned above, its synthesis is intimately related to that of GABA (see 
Fig. 2). 
 
 
Recently there has been increased interest in determining the exact mechanisms through which Mn exerts its 
neurotoxicity. Some studies imply that Mn exposure results in increased neuronal oxidative stress (Desole et al., 
1997; Stokes et al., 2000). Others propose that brain Mn accumulation disturbs the normal cellular metabolism 
and uptake of neurotransmitters (Miele et al., 2000; Montes et al., 2003; Fitsanakis and Aschner, 2005). As 
GABA, Glu and DA are all important neurochemicals in the basal ganglia circuitry, and are likely involved in 
manganism, it is important to examine the evidence concerning the ability of Mn to disrupt these vital 
neurochemicals. 
 
2. Mn neurotoxicity and GABA 
Although it has been known for many years that the early site of Mn accumulation is the globus pallidus, most 
research related to Mn neurotoxicity has focused on the dopaminergic system. The probably relates to the 
clinical similarities of manganism to IPD. Early studies using Mn as a substitute ion for calcium (Ca
2+
) reported 
that Mn inhibited the Ca
2+
- dependent release of GABA (Cotman et al., 1978). Others demonstrated that GABA 
transport was inhibited by MnCl2 in rat forebrain synaptosomes (Wong et al., 198 1), providing a link between 
Mn exposure and perturbations in GABA regulation. 
 
One of the first reports specifically examining the effect of Mn on the GABAergic system appeared in 1978 
(Bonilla, 1978), where Mn intoxication resulted in increased brain GABA content. Data generated from mice 
also demonstrated increased GABA levels in the striatum following exposure to either MnCl2 or MMT 
(Gianutsos and Murray, 1982). The authors do point out, however, that the observed changes in 
neurotransmitter levels occurred after treatment for either 6 months (MnCl2) or 3 weeks (MMT), but not with 
shorter exposure paradigms (1–2 months for MnCl2 and several days for MMT). It is perhaps not too surprising 
that neurotransmitter levels were unchanged following the shorter exposure of MnCl2, since the Mn food 
content (40 mg Mn/kg feed) was relatively low, and much of the metal would have been cleared by the liver. 
These data suggest increased striatal stimulation, perhaps from the glutamatergic cortical projections to the 
striatum (Fig. 1b). 
 
In contrast to these early reports Seth et al. (198 1) found that intraperitoneal injections of 6 mg Mn/kg for 15 
days resulted in diminished cerebellar GABA levels (Seth et al., 1981; Lipe et al., 1999). Another group 
confirmed these data, and also reported decreases in overall brain Glu decarboxylase (GAD) and GABA-
transaminase (GABA-T) levels subsequent to intraperitoneal injections of MnCl2 (10–20 mg Mn/kg) daily for 
30 days (Chandra et al., 1982). The authors point out that this data is in contrast to that of Bonilla (1978), but 
suggest that the close relationship of dopaminergic and GABAergic nuclei may reciprocally affect the other’s 
regulation. Chandra et al. (1982) subsequently verified the initial observations in animals on a low protein diet 
(Ali et al., 1983), or in developing, but not neonatal, rats (Seth and Chandra, 1984). The conflicting results 
could be due to differences in doses and treatment time. As the globus pallidus is the initial site of Mn 
accumulation, it may be that GABA output is primarily affected under these treatment conditions. 
 
Interestingly, Ali et al. (1983) report that Mn-induced decreases in brain GABA levels renders rats more 
susceptible to seizure activity. A similar phenomenon was reported in mice following exposure to MMT 
(Fishman et al., 1987). However, the latter group attributed the alterations in seizure activity to the potential 
ability of MMT to inhibit GABAA receptor ligand binding (Fishman et al., 1987). This hypothesis is consistent 
with work in non-human primates where GABAA receptor density was unchanged (suggesting problems with 
receptor binding and not receptor levels) following a 26-month dosing regime using 40 mg Mn/kg body mass 
(Eriksson et al., 1992). It must be noted, however, that both the dose and timeframe involved are higher and 
longer, respectively, than in earlier studies. 
 
Cell culture data suggest that striatal GABAergic neurons may be more susceptible to Mn exposure than 
mesencephalic dopaminergic neurons (Defazio et al., 1996). This supports the conclusions of Gwiazda et al. 
(2002) that low levels of Mn (three injections of 4.8 mg Mn/kg for 5 weeks) increased striatal GABA 
concentration, but not DA, even in rats pretreated with the dopaminergic neurotoxicant 6-hydroxydo-pamine (6-
OHDA) (Gwiazda et al., 2002). Whether DA or GABA levels are affected, however, appears to be strongly 
dependent on the treatment regime. For example, one lab reported perturbations in both systems (Tomas-
Camardiel et al., 2002). This group, however, used aged (18-month-old) rats, which may be a confounder when 
determining the role of DA in Mn toxicity in younger animals. 
 
Finally, Takeda et al. (2002, 2003) suggested that Mn injected into the striatum could be subsequently released 
in a sodium-dependent manner through striatal glutamatergic terminals. This release corresponded with a 
significant striatal GABA decrease in the microdialysate perfusate. Interestingly, no change was observed in 
striatal Glu, aspartate or glycine levels (Takeda et al., 2003). Notably, this suggests a mechanism whereby 
GABA release from the medium spiny neurons in the striatum may be regulated via alterations in the 
neighboring glutamatergic nuclei (Fig. 1b). 
 
Conflicting data exists as to whether Mn accumulation leads to decreases or increases in regional GABA levels. 
Nevertheless, it is clear that the GABAergic systems in the basal ganglia are affected. Future studies should 
determine whether GABA nuclei are directly affected by Mn accumulation, or if GABA perturbations are 
secondary to alterations in neighboring nuclei. Furthermore, the possibility that chronic low doses of Mn may 
specifically disrupt one neurotransmitter system (GABA), while acute exposures may affect others (DA) should 
also be tested. 
 
3. Mn neurotoxicity and glutamate 
Mn may exert its neurotoxic effects by facilitating the release of excessive amounts of Glu into the extracellular 
space. Increased extracellular Glu levels may lead to classical NMDA activation and downstream degenerative 
processes (Danbolt, 2001). Glu levels in the synapse are optimally controlled with 80% of the Glu being 
removed by astrocytes, a process predominantly carried out by the glutamate:aspartate trans-porter (GLAST). 
Mn exposure decreases astrocytic Glu uptake (Normandin and Hazell, 2002), as well as GLAST expression is 
these cells (Erikson et al., 2002b; Erikson and Aschner, 2003), suggesting a potential mechanism by which 
extracellular Glu levels could be increased. 
Mn exposure may also promote excitotoxicity through activation of Glu receptors (GluRs). Spadoni et al. 
(2000) observed an increase in the sensitivity of postsynaptic receptors to Glu, leading to abnormal activation of 
pallidal neurons treated with Mn (refer to Fig. 1b). This may partially explain the results of Takeda et al. (2002, 
2003) mentioned in the previous section. In contrast, others (Centonze et al., 2001) suggest that chronic Mn 
treatment leads to increases in the frequency and amplitude of spontaneous excitatory postsynaptic potentials 
(EPSPs) in the striatum, resulting from hyperactivity of corticostriatal neurons (Fig. 1b). Accordingly, up-
stream hyperactivity of cortical neurons, rather than postsynaptic sensitivity to Glu, likely contributes to the Mn 
intoxication observed in these neurons. 
 
In addition, Mn may affect the glutamatergic system via the over-activation of ionotropic GluRs. Hyperactivity 
of GluRs may lead to increased energy consumption due to an influx of sodium (Na
+
) and Ca
2+
 ions that must 
be actively pumped out of the cell (Castilho et al., 1999; Gavin et al., 1999; Slemmer et al., 2005). When cells 
are energy-compromised, it is known that Glu can ‘leak’ out of cells, resulting in increased extracellular Glu 
concentrations (Gavin et al., 1999; Erikson and Aschner, 2003; Slemmer et al., 2005). This suggests that Mn 
may exert its toxic effect by energy deprivation and mitochondrial arrest. 
 
Interestingly, Mn is concentrated in the mitochondria, leading to direct mitochondrial inhibition and decreased 
ATP levels (Gavin et al., 1999; Danbolt, 2001; Hazell, 2002; Normandin and Hazell, 2002). This process can 
lead to excessive mitochondrial Ca
2+ 
uptake to compensate for decreased Ca
2+
 levels. However, this 
compensation inhibits the cytoplasmic Ca
2+
 extrusion, a mechanism requiring ATP. The irreversible rise in Ca
2+
 
can initiate cell death (Castilho et al., 1999; Gavin et al., 1999). Additionally, Mn exposure alters cellular 
metabolism. Zwingmann et al. (2003, 2004) demonstrated both an increase in lactate synthesis and glycolytic 
flux from glucose oxidative metabolism in rats following Mn exposure (50 mg Mn/kg intraperitoneally/day for 
4 days). Mn also disrupts astrocyte metabolism (Zwingmann et al., 2003), potentially leading to the inability of 
astrocytes to provide neurons with the necessary components for neuro-transmitter metabolism (see Fig. 2). It is 
therefore likely that during Mn poisoning, cells could experience both Ca
2+
 loading within the cytoplasm 
concomitant with energy deprivation, producing a cytotoxic environment in which the cells can no longer 
survive. 
 
Finally, Cano et al. (1996) have shown that increases in extracellular Glu can lead to a decrease in glycine 
binding on the N-methyl-D-aspartate (NMDA) subtype of GluRs. This decline in glycine binding suggests that 
during Mn poisoning, an increase in Glu is offset by the attenuation of glycine binding, decreasing the affinity 
of NMDA receptors for Glu. Interestingly, the inability of glycine to bind to the receptor would counter other 
excitotoxic effects of excessive brain Mn levels. 
 
Due to the diversity of possibilities and contradictions concerning the mechanisms through which Mn perturbs 
the glutamatergic system, more studies need to focus on clarifying the exact nature of the interactions between 
Mn accumulation and Glu-induced excitotoxicity. Our current knowledge concerning Mn intoxication, as it 
relates to Glu, indicates that the presence of Mn: (1) reduces the ability of astrocytes to clear Glu from the 
extracellular space; (2) increases in the sensitivity of GluRs to Glu; (3) leads to inhibition of mitochondrial 
activity, causing increased production of reactive oxygen species as well as energy deprivation. 
 
4. Mn neurotoxicity and dopamine 
Research on the neurobiological consequences of Mn toxicity conducted in the last two decades has been 
predominantly directed at the effects of Mn on DA metabolism and its associated behavioral alterations. To 
date, it remains unknown how and why Mn accumulates in DA-rich brain regions in the basal ganglia, but this 
increased Mn is inversely related to DA levels both in neonatal (Tran et al., 2002) and older rats (Seth and 
Chandra, 1984). In this section, we highlight what is known about Mn neurotoxicity and DA biology, focusing 
mainly on the DA receptor and transporter proteins. 
 
The regulatory action of DA is mediated by at least five receptors classified into two subtypes: D1-like (D1 and 
D5) and D2-like (D2, D3 and D4) receptors (Neve and Neve, 1997; Vallone et al., 2000). The D1-like receptors 
are characterized by a long intracellular carboxy terminal, a short external amino terminal, and a short third 
intracellular loop, that is critical for proper functioning (Sibley et al., 1993; Neve and Neve, 1997). The D2-like 
receptors differ in that they have a short carboxy terminal, long amino terminal and a long third 
intracytoplasmic loop (Sibley et al., 1993; Neve and Neve, 1997). The D1-like receptors interact with G-proteins 
that stimulate adenylate cyclase activity, whereas D2-like receptors inhibit adenylate cyclase activity (Vallone et 
al., 2000). 
 
Most studies that have examined the effects of Mn neurotoxicity and DA receptors have focused on the D2 
receptor (Seth and Chandra, 1984; Bhargava, 1987; Eriksson et al., 1992). In general, however, they have been 
inconclusive. For example, Eriksson et al. (1992) reported that Mn intoxication does not significantly alter D2 
receptor levels, but rather D1 levels in the striatum of monkeys. Others report that striatal D2 receptor levels are 
significantly decreased due to Mn toxicity in the developing rat (Seth and Chandra, 1984). Interestingly, many 
of the behavioral alterations observed in subjects exposed to Mn are DA-related ones, particularly those 
implicating the D2 receptor. For example, locomotor and physical activity, both putative dopaminergic-type 
behaviors, are often impaired in Mn intoxicated rodents (Calabresi et al., 2001; Tran et al., 2002). 
 
Approximately 80% of extracellular DA is recycled into presynaptic neurons through a reuptake Na
+ 
co-
transporter, a 70 kDa protein that is both phosphorylated and glycosylated (Ciliax et al., 1995; Miller et al., 
1997). The DA transporter (DAT) is a member of the family of Na
+
/Cl--dependent transporters whose 
regulation includes both chronic and acute regulatory factors (reviewed in Mash and Staley, 1997). DAT 
density is greatest in caudate, putamen and nucleus accumbens, and increases throughout development to 
maximal levels in adulthood (Tarazi et al., 1998). Neurotoxicants, such as 1- methyl-4-phenylpyridium (MPP+) 
and paraquat (pesticide) are selectively lethal to dopaminergic neurons because they are transported by DAT 
(Snyder and D’Amato, 1986; Ritz et al., 1987). It has been hypothesized that Mn is also transported into 
dopaminergic neurons via DAT (Ingersoll et al., 1999). 
 
In order to test this hypothesis, Ingersoll et al. (1999) administered cocaine (a DAT inhibitor) or reserpine 
(effectively results in decreased DA concentrations) to rats exposed to intrathecal Mn (250 μg Mn/rat). Rats 
exposed to both drugs had a significant decrease in Mn accumulation in the ventral pallidum, suggesting that 
DAT and/or DA metabolism play a role in mediating Mn neurotoxicity. However, cocaine also affects other 
neurotransmitters, most notably serotonin and norepinephrine (Ritz et al., 1990). Thus, it is unclear as to 
whether a decrease in ventral pallidum Mn concentrations is directly related to the inhibition of DAT by this 
drug, or reflects the inhibition of serotonin and/or norepinephrine transporter functioning. 
 
Using DAT-knockout mice, we recently demonstrated that DAT is involved in the facilitation of striatal Mn 
accumulation, perhaps playing a critical role in Mn neurotoxicity mediation (Erikson et al., 2005). Specifically, 
when either wild-type or DAT-knockout mice were exposed to an acutely toxic dose of Mn (50 mg Mn/kg body 
mass), analysis of regional brain Mn concentrations indicated that DAT-knockout mice accumulated 
significantly less striatal Mn when compared to wild-type mice. Furthermore, this effect was only evident in the 
DAT-rich striatum and not other brain regions examined (Erikson et al., 2005). It should be noted that mice 
lacking DAT (DAT-knockout) have normal anatomical arrangements of dopaminergic cell bodies and 
projections (Jaber et al., 1999). Therefore, differences in cellular structure should not affect the differential 
uptake of Mn between DAT-knockout and wild-type mice. 
 
As previously mentioned, manganism shares neurological symptoms with IPD. While IPD is associated with 
decreased DAT density in the striatum, little is known about the effects of manganism on DAT density and/or 
functioning. Huang et al. (2003) examined striatal DAT density in Mn intoxicated patients. They found that, 
compared to controls, there was a slight decrease in DAT density, albeit statistically non-significant in this 
patient population (Huang et al., 2003). More importantly, these investigators showed that compared to patients 
with IPD, those with manganism have significantly more DAT in the striatum (Huang et al., 2003). This is 
corroborated by positron emission tomography (PET) studies with fluora-DOPA imaging in which patients with 
manganism show intact dopaminergic neurons, as opposed to those in patients with IPD who display diminished 
dopaminergic neuronal content (Calne et al., 1994; Pal et al., 1999). 
 
Taken together, these data strongly suggest that Mn neurotoxicity may be in part modulated by DAT. However, 
this needs to be confirmed by additional studies. It is also likely that one way in which Mn alters DA levels 
relates to its differential regulation of DA receptors. It could also be the case that alterations in DA receptors 
occur as a secondary response to potentially increased Glu activity from the subthalamic nucleus, although this 
has not been demonstrated. Thus, it is important to determine whether changes in receptor numbers are a 
primary or secondary effect of striatal Mn accumulation. 
 
5. Conclusions 
The literature strongly favors the view that high brain Mn levels affect all three of the major neurotransmitters 
in the basal ganglia circuitry. However, it is still uncertain as to what mechanisms are responsible for the effects 
of Mn in the brain. Although Mn accumulation occurs initially in the GABAergic globus pallidus, it seems 
likely that Mn also perturbs the glutamatergic neurotransmission in the cortex and striatum. Additionally, data 
suggest that, while DA is involved in acute Mn toxicity or the latter stages of manganism, it is plausible that 
GABAergic nuclei are actually more sensitive to this metal. 
 
Future experiments should focus on which of the basal ganglia nuclei are most susceptible to Mn, along a 
temporal exposure axis. Because of the propensity of Mn to accumulate in mitochondria (Gavin et al., 1999), it 
is likely that those basal ganglia nuclei with the highest energy requirements are the most vulnerable, but this 
has yet to be established. It is also important to determine the effects of pallidal GABA perturbation on other 
nuclei in the basal ganglia, and better explore the role of GABA and Mn-induced neurotoxicity. 
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